Literature DB >> 11192829

CA 15-3: a prognostic marker in breast cancer.

M J Duffy1, S Shering, F Sherry, E McDermott, N O'Higgins.   

Abstract

CA 15-3 (also known as MUC1) is the most widely used serum marker in breast cancer. MUC1 is a large transmembrane glycoprotein which is frequently overexpressed and aberrantly glycosylated in cancer. Physiologically, MUC1 appears to play a role in cell adhesion and the high levels present in cancer may be causally involved in metastasis. At present the main uses of CA 15-3 are in preclinically detecting recurrent breast cancer and monitoring the treatment of patients with advanced breast cancer. In a prospective study of 368 patients we show that patients with high preoperative levels of CA 15-3 (>30.4 U/mL) had a worse outcome than patients with low levels of the marker. In multivariate analysis CA 15-3 as a prognostic marker was independent of both tumor size and nodal status. Furthermore, in multivariate analysis the prognostic impact of CA 15-3 was stronger than that of tumor size and at least as strong as nodal status. CA 15-3 may thus be the first independent prognostic serum marker in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11192829     DOI: 10.1177/172460080001500410

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   3.248


  34 in total

1.  Comparison of N-linked Glycoproteins in Human Whole Saliva, Parotid, Submandibular, and Sublingual Glandular Secretions Identified using Hydrazide Chemistry and Mass Spectrometry.

Authors:  Prasanna Ramachandran; Pinmanee Boontheung; Eric Pang; Weihong Yan; David T Wong; Joseph A Loo
Journal:  Clin Proteomics       Date:  2008-12       Impact factor: 3.988

Review 2.  Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence.

Authors:  Alyssa B Chinen; Chenxia M Guan; Jennifer R Ferrer; Stacey N Barnaby; Timothy J Merkel; Chad A Mirkin
Journal:  Chem Rev       Date:  2015-08-27       Impact factor: 60.622

Review 3.  MUC1 (CD227): a multi-tasked molecule.

Authors:  Vasso Apostolopoulos; Lily Stojanovska; Sharron E Gargosky
Journal:  Cell Mol Life Sci       Date:  2015-08-21       Impact factor: 9.261

Review 4.  Protein glycosylation in cancer.

Authors:  Sean R Stowell; Tongzhong Ju; Richard D Cummings
Journal:  Annu Rev Pathol       Date:  2015       Impact factor: 23.472

5.  DecoyDeveloper: An On-Demand, De Novo Decoy Glycopeptide Generator.

Authors:  Joshua T Shipman; Xiaomeng Su; David Hua; Heather Desaire
Journal:  J Proteome Res       Date:  2019-06-03       Impact factor: 4.466

6.  Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum.

Authors:  John B Welsh; Lisa M Sapinoso; Suzanne G Kern; David A Brown; Tao Liu; Asne R Bauskin; Robyn L Ward; Nicholas J Hawkins; David I Quinn; Pamela J Russell; Robert L Sutherland; Samuel N Breit; Christopher A Moskaluk; Henry F Frierson; Garret M Hampton
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-06       Impact factor: 11.205

Review 7.  Glycans and glycoproteins as specific biomarkers for cancer.

Authors:  Muchena J Kailemia; Dayoung Park; Carlito B Lebrilla
Journal:  Anal Bioanal Chem       Date:  2016-09-03       Impact factor: 4.142

8.  Serum thymidine kinase 1 activity in solid tumor (breast and colorectal cancer) patients treated with adjuvant chemotherapy.

Authors:  M Bolayirli; C Papila; G G Korkmaz; B Papila; F Aydoğan; A Karataş; H Uzun
Journal:  J Clin Lab Anal       Date:  2013-05       Impact factor: 2.352

9.  Correlation study of Carcino Embryonic Antigen & Cancer Antigen 15.3 in pretreated female breast cancer patients.

Authors:  K Thriveni; Lakshmi Krishnamoorthy; Girija Ramaswamy
Journal:  Indian J Clin Biochem       Date:  2007-03

10.  Tumour markers: An overview.

Authors:  T Malati
Journal:  Indian J Clin Biochem       Date:  2007-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.